Dept of Pathology, University of Alabama at Birmingham, AL, USA.
Am J Clin Pathol. 2011 Aug;136(2):239-46. doi: 10.1309/AJCP0Y5QWWYDKCJE.
Our aim was to compare the usefulness of fatty acid synthase (FASn) with that of α-methylacyl coenzyme-A racemase (AMACR) in the diagnosis of prostatic adenocarcinoma. The expression of these 2 markers was compared in a tissue microarray containing 62 foci of benign glands and 36 foci of prostatic adenocarcinoma. Similar to AMACR, there was significantly higher FASn expression in adenocarcinoma compared with that in benign glands. The optimal accuracy rate and area under curve (AUC) by receiver operating characteristic analysis for FASn were not significantly different from those for AMACR (accuracy, 80% vs 87%; AUC, 0.942 vs 0.956; P for both, > .05). Moreover, in cases with coexistent malignant and benign glands on the same core, FASn could selectively distinguish a proportion of cases (17/21 [81%]) similar to using AMACR. We conclude that FASn may aid in the diagnosis of prostatic adenocarcinoma, at least to supplement AMACR as another positive marker of carcinoma and potentially increase diagnostic accuracy.
我们的目的是比较脂肪酸合酶（FASn）与α-甲基酰基辅酶 A 消旋酶（AMACR）在前列腺腺癌诊断中的作用。在包含 62 个良性腺体焦点和 36 个前列腺腺癌焦点的组织微阵列中比较了这 2 种标志物的表达。与 AMACR 相似，腺癌中 FASn 的表达明显高于良性腺体。FASn 的最佳准确率和曲线下面积（AUC）与 AMACR 的无显著差异（准确率分别为 80%和 87%，AUC 分别为 0.942 和 0.956，两者均为 P>0.05）。此外，在同一核心中同时存在恶性和良性腺体的情况下，FASn 可以选择性地鉴别一部分病例（17/21 [81%]），类似于使用 AMACR。我们得出结论，FASn 可能有助于诊断前列腺腺癌，至少可以补充 AMACR 作为癌的另一个阳性标志物，并可能提高诊断准确性。
